Strong Prescription Growth and Competitive Advantage Drive Buy Rating for Arcutis Biotherapeutics
Mizuho Securities analyst Uy Ear has maintained their bullish stance on ARQT stock, giving a Buy rating on November 11.Don't Miss our Black ...
Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour
ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitisZORYVE, a next-generation topical phosphodiesterase-4 ...
Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?
Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.
Organon: 7% Yield, 4x P/E, Big Upside Potential
Organon is a strong investment opportunity with a high yield, diversified portfolio, steady performance, and transformative ...